NSE: CIPLA | BSE: 500087

Strong Performer, Getting Expensive

Download real time

1574.00 2.00 (0.13%)

1.3M NSE+BSE Volume

NSE 29 Jul, 2025 3:31 PM (IST)

127,140

Market Cap

High in industry

0.7

Beta 1Year

Very Low volatility

Target Upgrade

Nuvama maintains a 'Hold' rating on Cipla; raises the target price to Rs 1,651 See details

Cipla Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for CIPLA, BSE:500087 Cipla Ltd.

Cipla Ltd.

24 Feb 2016

1574.00

0.13%

Cipla Ltd- Research Report

Buy: Cipla Ltd.

Angel Broking

Cipla has posted a lower-than-expected set of numbers for 3QFY2016. Sales came in at Rs3,027cr (V/s `3,367cr expected) V/s Rs2,625cr in 3QFY2015, a yoy growth of 15.3%, mainly led by exports. On the operating front, the OPM came in at 12.0% V/s 19.9% expected and V/s 15.7% in 3QFY2015. According to the Management, the revenues took a 2.5% impact on account of change in distribution policy and an ~0.7% impact on back of currency impact of ZAR. Thus, the Adj. net profit came in at Rs343cr V/s Rs400cr expected and V/s Rs328cr in 3QFY2015, registering a yoy growth of 4.7%. We maintain our Buy on the stock with a price target of Rs605. Results better than expectations on the OPM front: Sales for the quarter came in at Rs3,027cr (V/s Rs3,367cr expected) V/s Rs2,625cr in 3QFY2015, a yoy growth of 15.3%, mainly led by exports. Domestic sales (Rs1,194cr) posted a dip of 0.4%, while exports (Rs1,833cr) posted a yoy growth of 28.5%. On the operating front, the OPM came in at 12.0% V/s 19.9% expected and V/s 15.7% in 3QFY2015. The lower OPM yoy is owing to decline in the GPM which came in at 58.9% V/s 63.9% expected and...

Number of FII/FPI investors increased from 1114 to 1124 in Jun 2025 qtr.

Cipla Ltd.

12 Feb 2016

1574.00

0.13%

Cipla

Buy: Cipla Ltd.

Target

ICICI Securities Limited

Cipla Ltd. has an average target of 1702.12 from 8 brokers.

Cipla Ltd.

11 Feb 2016

1574.00

0.13%

Cipla (3QFY16): Better days ahead. Maintain BUY

Buy: Cipla Ltd.

Target

HDFC Securities

Ciplas 3QFY16 numbers took a hit owing to several factors, including (1) One-time impact of change in distribution policy in the domestic business, (2) Earlier-than-expected erosion in Nexium, (3) Increase in R&D; spend, (4) Currency devaluation in South Africa, (5) Decline in API sales and (6) Increased spending on consumer and biologics business.

Axis Direct released a Buy report for Cipla Ltd. with a price target of 1700.0 on 28 Jul, 2025.

Cipla Ltd.

11 Feb 2016

1574.00

0.13%

Cipla 11Feb2016

Buy: Cipla Ltd.

Target

Phillip Capital

9 Broad base growth in US, South Africa, Europe and other emerging markets led to robust43%yoyjumpinformulationexports Key highlights: Revenues were 3% below our estimates due to onetime impact of...

Axis Direct released a Buy report for Cipla Ltd. with a price target of 1700.0 on 28 Jul, 2025.

Cipla Ltd.

02 Dec 2015

1574.00

0.13%

Cipla (Update): At the threshold. BUY

Buy: Cipla Ltd.

Target

HDFC Securities

Consolidation of Invagen, launch of a host of high- value products in the US (including respiratory, oncology and complex oral solids) and operating leverage are the key earnings growth drivers for Cipla over the next two years. We believe these will help the company deliver ~25% EPS CAGR over FY16-18E. Our earnings estimates for FY16E/17E/FY18E are reset to Rs 24.2/30.5/38.6. We assume coverage on Cipla with a BUY rating. Our TP is Rs 760 (22x 1-year forward rolling EPS).

Axis Direct released a Buy report for Cipla Ltd. with a price target of 1700.0 on 28 Jul, 2025.

Cipla Ltd.

10 Nov 2015

1574.00

0.13%

Cipla Ltd- Research Report

Hold: Cipla Ltd.

Angel Broking

For 2QFY2016, Cipla posted numbers more or less in line with our expectations on the sales and net profit front while beating our estimates on the OPM front. The company posted sales of Rs3,362cr V/s Rs3,343cr expected and V/s Rs2,630cr in 2QFY2015, a yoy growth of 27.8%. On the operating front, the OPM came in at 20.8% V/s 16.0% in 2QFY2015 and V/s an expected 19.7%, driven by gross margin expansion and higher sales growth. Thus, the Net Profit came in at Rs432cr V/s an expected Rs458cr and V/s Rs299cr in 2QFY2015, a yoy growth of 44.4%. The Management reiterated its guidance of sales growth of 22% in FY2016 and EBDITA margin improvement of 100-150bp. We currently have a Neutral rating on the stock. Results better than expectations on the OPM front: The company posted sales of Rs3,362cr V/s Rs3,343cr expected and V/s Rs2,630cr in 2QFY2015, a yoy growth of 27.8%. The growth on the top-line came through a 52.3% yoy growth in exports driven by formulation exports (on back of generic Nexium). Export API, on the other hand posted a 61.4% yoy growth during the quarter. Domestic formulation (Rs1,262cr) posted a flat growth of 0.9% yoy. On the operating...

Cipla Ltd. is trading above all available SMAs

Cipla Ltd.

06 Nov 2015

1574.00

0.13%

Cipla

Buy: Cipla Ltd.

ICICI Securities Limited

Axis Direct released a Buy report for Cipla Ltd. with a price target of 1700.0 on 28 Jul, 2025.

Cipla Ltd.

05 Nov 2015

1574.00

0.13%

Cipla -2QFY16 Result Update

Neutral: Cipla Ltd.

Target

Reliance Securities

Nexium cools in 2Q; scale up in respiratory remains critical ffInvagen could act as a transformational catalyst, albeit in the long term, with US contributing 20% to overall sales. However, we assess that most of the products are me-too oral solids lacking differentiation. Besides, it has not received any...

Number of FII/FPI investors increased from 1114 to 1124 in Jun 2025 qtr.

Is Cipla Ltd. worth buying?

618 Votes:

Buy 75.73%

Sell 14.08%

Hold 10.19%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf